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Abstract
 
Insulin-induced vasodilatation is sensitive to nitric oxide (NO) synthase (NOS) inhibitors.
However, insulin is unable to relax isolated arteries or to activate endothelial NOS in endothelial
cells. Since insulin can enhance platelet endothelial NOS activity, we determined whether insulin-
induced vasodilatation can be attributed to a NO-dependent, platelet-mediated process.
Insulin failed to relax endothelium-intact rings of porcine coronary artery. The supernatant
from insulin-stimulated human platelets induced complete relaxation, which was prevented by
preincubation of platelets with a NOS inhibitor, the soluble guanylyl cyclase inhibitor, NS
2028, or the G kinase inhibitor, KT 5823, and was abolished by an adenosine A
 
2A
 
 receptor
antagonist. Insulin induced the release of adenosine trisphosphate (ATP), adenosine, and sero-
tonin from platelet-dense granules in a NO-dependent manner. This response was not detected
using insulin-stimulated platelets from endothelial NOS
 
 
 
/
 
 
 
 mice, although a NO donor elicited
ATP release. Insulin-induced ATP release from human platelets correlated with the association
of syntaxin 2 with the vesicle-associated membrane protein 3 but was not associated with the
activation of 
 
 
 
IIb
 
 
 
3
 
 integrin. Thus, insulin elicits the release of vasoactive concentrations of
ATP and adenosine from human platelets via a NO–G kinase–dependent signaling cascade.
The mechanism of dense granule secretion involves the G kinase–dependent association of
syntaxin 2 with vesicle-associated membrane protein 3.
Key words:
 
 
 
IIb
 
 
 
3
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Introduction
 
Several mechanisms have been proposed to account for
insulin-induced vasodilatation, including an interaction
with the sympathetic nervous system at the vascular level
(1), the activation of ion channels (2), in particular adenosine
trisphosphate (ATP)–dependent K
 
 
 
 channels (3), the release
of adenosine (4, 5), and an increase in the generation of nitric
oxide (NO) by the vascular endothelium (6, 7). Although
the latter mechanism could account for the finding that the
insulin-induced vasodilatation observed in vivo is sensitive
to NO synthase (NOS) inhibitors (7, 8), the acute application
of insulin to endothelial cells or isolated arteries does not
generally elicit an immediate increase in NO production
(9, 10) or potentiate the vasodilator response to endothelial
cell agonists such as acetylcholine or a Ca
 
2
 
 
 
 ionophore
(10). Indeed, acute effects of insulin on vascular tone have
also been attributed to endothelium-independent actions
related to alterations in smooth muscle calcium (11) and/or
the activation of potassium channels (2). Moreover, there is
also some doubt as to whether or not the effects of insulin
recorded in vivo can be attributed to a direct action of the
hormone at its site of application, since pronounced insulin-
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Abbreviations used in this paper:
 
 ACD, acid citrate dextrose; ADP, adenosine
diphosphate; AMPK, adenosine monophosphate–activated protein kinase;
ATP, adenosine trisphosphate;
 
 
 
CPT, cylcopentyl-theophylline; CSC,
8-(3-chlorostyryl)caffeine; cyclic GMP, guanosine-3
 
 
 
,5
 
 
 
 cyclic monophos-
phate; DETA-NONOate, diethylamine nonoate; eNOS, endothelial NOS;
L-NA, N
 
 
 
nitro-
 
l
 
-arginine;  NO, nitric oxide; NOS, NO synthase;
SNARE, 
 
N
 
-ethylmaleimide–sensitive factor attachment protein receptor;
Sp-cGMPS, guanosine-3
 
 
 
,5
 
 
 
 cyclic monophosphorothioate, Sp isomer;
t-SNARE, target membrane SNARE; VAMP, vesicle-associated membrane
protein; VASP, vasodilator-stimulated phosphoprotein. 
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induced vasodilatation has been reported to require sys-
temic, and not local, hyperinsulinemia (12) and may be de-
pendent on the local uptake of 
 
d
 
-glucose (13).
Summarizing the available data, it appears that a role for
NO in mediating insulin-induced changes in blood flow
can only be demonstrated in vivo by comparing responses
in the absence and presence of a NOS inhibitor. This
means that the evidence that insulin-induced vasodilatation
can be attributed to the activation of endothelial NOS
(eNOS) in endothelial cells is only circumstantial. There-
fore, it is possible that insulin activates eNOS in blood cells,
e.g., in platelets, and that platelet-derived NO is responsi-
ble for the vasodilator effects of insulin. Alternatively, NO
generated within platelets may affect the release of a more
stable platelet-derived relaxing factor. Indirect evidence
suggests that the latter possibility is the most likely, since
platelet-derived adenosine diphosphate (ADP) (14) and
other dinucleotides (15) and serotonin (16) have been re-
ported to mediate platelet-induced vasodilatation. There-
fore, the aim of the present investigation was to determine
whether or not insulin affects vascular tone in a platelet-
and NO-dependent manner.
 
Materials and Methods
 
Materials.
 
Citric acid and 3-([3-cholamidopropyl] dimeth-
ylammonio)-1-propanesulfonate were from Applichem;
AACOCF
 
3
 
, Ca-Titriplex, NS2028, and KT5823 were from
Merck; U46619 was from Alexis; and N
 
 
 
nitro-
 
l
 
-arginine (L-
NA) was from Fluka. Diethylamine nonoate
 
 (
 
DETA-NONO-
ate), (
 
R
 
)-
 
p
 
-8-(4-chlorophenylthio)cGMP, guanosine-3
 
 
 
,5
 
 
 
 cyclic
monophosphorothioate, Sp isomer (Sp-cGMPS), and all other
drugs were from Sigma-Aldrich.
 
Platelet Isolation.
 
Blood was donated by healthy individuals
who had not taken any medication known to interfere with
platelet aggregation for at least 10 d. 50 ml blood was collected
into acid citrate dextrose (ACD: 85 mmol/L sodium citrate, 65
mmol/L citric acid, and 125 mmol/L dextrose; 5 ml ACD:50 ml
of blood). Platelet-rich plasma was obtained by centrifugation at
130 
 
g
 
 for 20 min. Plasma-free platelet suspensions were obtained
by centrifugation (900 
 
g
 
, 7 min) of the platelet-rich plasma, and
the resulting pellet was suspended in either Tyrode’s solution
(132 mmol/L NaCl, 4 mmol/L KCl, 1.6 mmol/L CaCl
 
2
 
, 0.98
MgCl
 
2
 
, 23.8 mmol/L NaHCO
 
3
 
, 0.36 mmol/L NaH
 
2
 
PO
 
4
 
, 10
mmol/L glucose, 0.05 mmol/L Ca-Titriplex, and gassed with
20% O
 
2
 
, 5% CO
 
2
 
, and 75% N
 
2
 
 to give a pO
 
2
 
 of 
 
 
 
140 mmHg
and pH 7.4 at 37
 
 
 
C) or a Hepes-modified Tyrode solution (132
mmol/L NaCl, 4 mmol/L KCl, 1 mmol/L CaCl
 
2
 
, 0.5 mmol/L
MgCl
 
2
 
, 9.5 mmol/L Hepes, 0.36 mmol/L NaH
 
2
 
PO
 
4
 
, and 5
mmol/L glucose). After a further centrifugation step (900 
 
g
 
, 4
min), washed platelets were resuspended in Hepes-Tyrode or Ty-
rode’s solution to achieve a final platelet density of 3 
 
 
 
 10
 
8
 
/ml.
Platelet suspensions were allowed to equilibrate (37
 
 
 
C, 30 min) in
the absence or presence of different inhibitors before stimulating
with insulin (1 nmol/L–1 
 
 
 
mol/L) for 10 min. After stimulation,
the platelet suspension was centrifuged for 2 min at 900 
 
g
 
, and 2
ml of the supernatant was added to U46619-precontracted arter-
ies mounted in an organ chamber (final volume, 10 ml). The final
dilution of the platelet-derived relaxing factor (starting from 50
ml whole blood) was approximately eightfold. In the platelet
preparations used throughout (from 53 different donors), the av-
erage number of platelets was 393/nL versus 0.03 leukocytes/nL
(of which 10–20% were monocytes). There was no difference in
the purity of preparations which responded to insulin versus those
which did not.
 
Cyclic Guanosine-3
 
 
 
,5
 
 
 
 Cyclic Monophosphate
 
 
 
Assay.
 
Cyclic
guanosine-3
 
 
 
,5
 
 
 
 cyclic monophosphate
 
 
 
(GMP) levels were deter-
mined in isobutyl methylxanthine (3 
 
 
 
mol/L IBMX)-treated
platelets using a specific radioimmunoassay (PerkinElmer).
 
Vascular Reactivity Studies.
 
Second branches of coronary ar-
teries (internal diameter 300–500 
 
 
 
m) were dissected from the
hearts of freshly slaughtered pigs, cleaned of adventitial adipose
and connective tissue, and cut into 4-mm-long segments. Coro-
nary artery rings were mounted on stainless steel triangles con-
nected to a force transducer (Hugo Sachs Elektronik-Harvard
Apparatus) and a rigid support for measurement of isometric force
in organ baths containing Tyrode’s solution. Passive tension was
gradually adjusted over a 60-min period to 1 g; thereafter, arterial
rings were repeatedly exposed to a modified Tyrode’s solution
rich in KCl (80 mmol/L) until stable contractions were obtained
as described (17). The presence of functional endothelium was as-
sessed in all preparations by the ability of bradykinin (1 
 
 
 
mol/L)
to induce the relaxation of vessels precontracted with U46619
(0.1 
 
 
 
mol/L), and vessels that exhibited 
 
 
 
80% relaxation were
discarded. After additional washing and reestablishment of base-
line tension, vessels were contracted to 80% of the maximal KCl-
induced contraction, and the relaxant response to the cumulative
application of either adenosine (0.1–30 
 
 
 
mol/L) or ATP (0.1–30
 
 
 
mol/L) or to the bolus application of platelet supernatant (2 ml)
was determined. In some experiments, the endothelium was re-
moved by intraluminal perfusion with 3-([3-cholamidopropyl]
dimethylammonio)-1-propanesulfonate (0.5% in Tyrode’s solu-
tion) for 30 s. In this case, all rings which responded to the appli-
cation of bradykinin were discarded.
 
ATP, Adenosine, and Serotonin Assays.
 
The release of ATP
into the platelet supernatant was determined using a luciferin/lu-
ciferase ATP kit (Enliten
 
®
 
 ATP assay system; Promega). For this
purpose, 500 
 
 
 
l aliquots of platelet supernatant containing the ec-
tonucleotidase inhibitor ARL 67156 (10 
 
 
 
mol/L) were mixed
with 100 
 
 
 
l of ATP assay buffer, and light emission was measured
using a luminometer. Raw data were collected as relative light
units integrated over 10 s and calibrated with the aid of a standard
ATP calibration curve.
The concentration of adenosine in the supernatant from insu-
lin-stimulated platelets was determined by HPLC as described
(18). Serotonin in the platelet supernatant was quantified using a
commercially available ELISA (IBL).
 
Preparation of Murine Platelets.
 
Wild-type (c57 black b6) and
age- and gender-matched eNOS
 
 
 
/
 
 
 
 mice (obtained from the
Heinrich-Heine-Universität) were anesthetized with isoflurane,
and blood was immediately collected in 10% ACD by punctuat-
ing the right cardiac ventricle. Approximately 500 
 
 
 
l of murine
blood was centrifuged at 130 
 
g
 
 for 20 min and thereafter at 900 
 
g
 
for 7 min. Platelets were suspended in Hepes-Tyrode solution,
and after a further centrifugation step (900 
 
g
 
, 4 min), the volume
of Hepes-Tyrode solution was adjusted to give a final platelet
count of 2 
 
 
 
 10
 
8
 
/ml. Platelet suspensions were allowed to equil-
ibrate (37
 
 
 
C, 30 min) in the absence or presence of different in-
hibitors before stimulating with insulin (1 
 
 
 
mol/L) or DETA-
NONOate (1 
 
 
 
mol/L) for 10 min. After stimulation, the platelet
suspension was centrifuged for 2 min at 900 
 
g
 
, and the superna-
tant was used for ATP measurement.
 
Immunoblotting and Immunoprecipitation of Syntaxin 2.
 
Platelets
were solubilized in buffer of the following composition: 20 
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mmol/L Tris-HCl, 150 mmol/L NaCl, NaPPi 10 mmol/L, 20
mmol/L NaF, 25 mmol/L 
 
 
 
-glycerophosphate, 2 mmol/L so-
dium orthovanadate, 1% Nonidet, 10 nmol/L okadaic acid, 100
 
 
 
g/ml leupeptin, 100 
 
 
 
g/ml aprotinin, and 100 
 
 
 
mol/L phenyl-
methylsulfonyl fluoride. Then, platelets were left on ice for 30
min and centrifuged at 13,000 rpm for 10 min, and the superna-
tants were used for immunoprecipitation. In some experiments,
syntaxin 2 was immunoprecipitated with a monoclonal anti–syn-
taxin 2 antibody (Santa Cruz Biotechnology, Inc.) after preclear-
ing of the cell lysate with a mixture of protein A–G sepharose.
Platelet lysates or immunoprecipitates were boiled in SDS sample
buffer, separated by SDS-PAGE, transferred to a nitrocellulose
membrane as described (19), and visualized using a commercially
available enhanced chemiluminescence kit (Amersham Bio-
sciences). Samples were blotted twice, and the blots probed with
the respective antibodies. Phosphorylated vasodilator-stimulated
phosphoprotein (VASP) was detected using a specific monoclonal
antibody (Nanotools), and the equal loading of each lane was as-
sessed using an antibody recognizing total VASP protein (Trans-
duction Laboratories). Syntaxin 2 immunoprecipitates were also
blotted twice, one membrane being used to detect vesicle-asso-
ciated membrane protein (VAMP)-3/cellubrevin, using a specific
antibody (Abcam), and the other to detect syntaxin 2 and monitor
the efficiency of the immunoprecipitation.
 
Flow Cytometry.
 
Platelet suspensions (100 
 
 
 
L, containing 2 
 
 
 
10
 
6
 
 platelets) were prepared as described and incubated for 10
min at room temperature in the dark with either a FITC-conju-
gated anti–human PAC-1 antibody (BD Biosciences), a FITC-
conjugated anti–human P-selectin antibody (BD Biosciences) or
matched mouse IgM and IgK isotype controls. Platelets were
then stimulated for 10 min with either insulin (1 
 
 
 
mol/L),
DETA-NO (1 
 
 
 
mol/L), or thrombin (0.1 U/ml) in the presence
of H-Gly-Pro-Arg-pro-NH
 
2
 
 (5 mmol/L) to prevent fibrin poly-
merization and platelet aggregation. After stimulation, the sam-
ples were fixed by the addition of 1 ml of paraformaldehyde (2%,
vol/vol) in PBS and analyzed by flow cytometry (FACSCalibur
flow cytometer; BD Biosciences) within 2 h of stimulation. The
FITC channel baseline value for resting and agonist-stimulated
platelets was set using unlabeled platelets. An average of 30,000
platelet events per sample was collected and analyzed for PAC-1
and P-selectin fluorescence intensity.
 
Statistical Analysis.
 
R
 
max
 
 represents the maximal relaxation re-
corded in response to the cumulative addition of a given agonist.
Data are expressed as mean 
 
 
 
 SEM, and statistical evaluation was
performed using Student’s 
 
t
 
 test for unpaired data, one-way anal-
ysis of variance (ANOVA) followed by a Bonferroni 
 
t
 
 test, or
ANOVA for repeated measures, where appropriate. Values of
P
 
 
 
  
 
0.05 were considered statistically significant.
 
Results
 
Relaxing Factor Derived from Insulin-stimulated Washed Hu-
man Platelets.
 
The direct application of insulin (1 
 
 
 
mol/
L) to precontracted, endothelium-intact, small porcine cor-
onary artery rings failed to elicit any change in tone (Fig. 1
a). However, the addition of washed human platelets to the
organ chamber resulted in platelet aggregation, as a conse-
quence of the activation by the thromboxane analogue
used to precontract the coronary arteries (not depicted).
However, the supernatant from insulin (1 mmol/L)-stimu-
lated human platelets elicited the rapid relaxation of arterial
rings; R
 
max
 
 values were 11.4 
 
 
 
 3.1 in response to the su-
pernatant of unstimulated platelets versus 68.5 
 
 
 
 8.3% in
response to the supernatant from insulin-stimulated plate-
lets. The supernatant from insulin-stimulated platelets,
which were pretreated with the NOS inhibitor L-NA (300
 
 
 
mol/L, 30 min), failed to relax coronary artery rings. The
effect of insulin on the release of the platelet-derived relax-
ing factor was concentration dependent, and a small but
significant relaxation was observed in response to the appli-
cation of supernatant removed from platelets stimulated
with 1 nmol/L insulin (Fig. 1 c).
There were marked differences in the responses observed
to insulin treatment between platelets from different do-
nors, so that responders (65% of all preparations), where the
supernatant from insulin-stimulated platelets elicited a re-
laxation of 
 
 
 
60%, and nonresponders (35% of all prepara-
tions), where the relaxation was generally 
 
 
 
20%, could be
identified. The donor-dependent ability of the supernatant
from these platelets to release a relaxing factor was also cor-
related with the ability of insulin to inhibit thrombin-
induced platelet aggregation (not depicted).
 
Pharmacological Characterization of the Pathway Involved in
the Insulin-induced Release of a Platelet-derived Relaxing Fac-
tor. The experiments using L-NA suggested that the acti-
vation of NOS was involved in regulating the release of a
relaxing factor from insulin-stimulated platelets. To clarify
this point, we assessed cyclic GMP levels in insulin-stimu-
lated platelets. Cyclic GMP levels were 20.9  1.4, 40.6  
Figure 1. Relaxing factor derived from insulin-stimulated washed human
platelets. (a) Original tracings and (b) statistical summary showing the effect
of the direct application of human insulin (1  mol/L), the supernatant
from unstimulated platelets (Sol), the supernatant from insulin-stimulated
(1  mol/l, 10 min) platelets, and from platelets stimulated with insulin in
the presence of L-NA (300  mol/L) on the tone of endothelium-intact
small porcine coronary arteries precontracted with the thromboxane analogue
U46619. (c) Statistical summary showing the concentration-dependent
effect of insulin (1 nmol/L–1  mol/L) on the release of a relaxing factor
from platelets. The results shown represent the mean   SEM of data
obtained in six independent experiments; *P   0.05, **P   0.01, and
***P   0.001 versus the response obtained using the supernatant from
unstimulated platelets (Sol).NO-dependent Release of ATP and Adenosine from Insulin-stimulated Platelets 350
2.7, 20.1   1.1, and 19.5   0.9 fmol/mg protein in the
presence of solvent, insulin, L-NA, and insulin plus L-NA,
respectively (P   0.01, n   5).
When the soluble guanylyl cyclase inhibitor, NS2028
(10   mol/L), or the G kinase inhibitors, KT 5823 (1
 mol/L) or Rp-8CPT-cGMPs (10  mol/L), were present
throughout the platelet stimulation and the organ chamber
experiments, the relaxation of porcine coronary artery rings
was significantly attenuated. However, when these com-
pounds were present in the organ chamber but not present
throughout the preparation of the platelet supernatant, no
effect on the insulin-induced release of a platelet-derived
relaxing factor was observed (Fig. 2 a).
Pretreatment of washed human platelets with either the
cyclooxygenase inhibitor diclofenac (10  mol/L, 30 min),
the phospholipase A2 inhibitor AACOCF3 (3  mol/L, 30
min), or the adenylyl cyclase inhibitor 2 ,3 -dideoxyaden-
osine (100  mol/L, 30 min) did not affect the insulin (1
 mol/L)-induced release of a relaxing factor from platelets
(Fig. 2 b). However, the adenosine monophosphate–acti-
vated protein kinase (AMPK) inhibitor iodotubercidin (1
 mol/L) and the phosphatidylinositol 3-kinase inhibitor
wortmannin (40 nmol/L), which attenuate the insulin-
induced phosphorylation and activation of eNOS in plate-
lets (20), attenuated the insulin-induced release of a plate-
let-derived relaxing factor (Fig. 2 c).
Although the application of insulin to platelets stimulates
platelet eNOS, the relatively long preparation time of the
Figure 2. Pharmacological characterization of the pathway involved in
the insulin-induced release of a platelet-derived relaxing factor. (a) Effect
of the guanylyl cyclase inhibitor, NS 2028 (NS, 10  mol/L, 30 min), and
the G kinase inhibitors, KT 5823 (KT, 1  mol/L, 30 min) and Rp-
8CPT-cGMPs (Rp, 10  mol/L, 30 min), on the insulin (1  mol/L, 10
min)-induced release of a relaxing factor from washed human platelets,
i.e., inhibitors applied to the platelet donor and the detector artery ring
compared with the effects observed when the inhibitors were applied
only to the detector ring. (b) Statistical summary showing the effect of
L-NA (300  mol/L, 30 min), diclofenac (Dl, 10  mol/L, 30 min), the
phospholipase A2 inhibitor AACOCF3 (AA, 3  mol/L, 30 min), and the
adenylyl cyclase inhibitor 2 ,3 -dideoxyadenosine (DDA, 100  mol/L,
30 min) on the insulin (1  mol/L, 10 min)-induced release of a relaxing
factor from washed human platelets. (c) Summary showing the effect of
the AMPK inhibitor iodotubercidin (Iodo, 1  mol/L, 30 min) and the
phosphatidylinositol 3-kinase inhibitor wortmannin (Wort, 40 nmol/L,
30 min) on the insulin (1  mol/L, 10 min)-induced release of a relaxing
factor from washed human platelets. The results shown represent the
mean   SEM of data obtained in five to seven independent experiments.
**P   0.01 and ***P   0.001 versus the response obtained using the
supernatant from unstimulated platelets (Sol).
Figure 3. Pharmacological characterization of the platelet-derived
relaxing factor. (a) Effect of the nonselective adenosine receptor antagonist
CPT (10  mol/L, 30 min) and the selective A2 receptor antagonist CSC
(1  mol/L, 30 min) on the relaxation elicited by a factor derived from
insulin (1  mol/L, 10 min)-stimulated washed human platelets. (b) Effect
of inclusion of adenosine deaminase (50 U/ml) on the relaxing effect of
the supernatant from insulin-stimulated platelets. (c–f) Effect of adenosine
receptor antagonists on the adenosine- and ATP-induced relaxation of
the porcine coronary artery. Endothelium-intact rings of porcine coro-
nary artery were preconstricted with U46619 (0.01–0.5  mol/L), and
concentration–relaxation curves to adenosine (c and d) and ATP (e and f)
were obtained. Experiments were performed in the absence (CTL) and
the presence of CPT (10  mol/L) or CSC (1  mol/L). The results
shown represent the mean   SEM of data obtained in six to eight inde-
pendent experiments. *P   0.05 and ***P   0.001 versus the response
obtained in the absence of inhibitor.Randriamboavonjy et al. 351
platelet supernatant together with the insensitivity of the
platelet supernatant-induced relaxation of coronary arteries
to guanylyl cyclase and G kinase inhibition, imply that NO
itself is not the platelet-derived relaxing factor.
Characterization of the Platelet-derived Relaxing Factor.
Both the nonselective adenosine receptor antagonist cylco-
pentyl-theophylline (CPT, 10  mol/L) and the selective
A2 adenosine receptor antagonist 8-(3-chlorostyryl)caf-
feine (CSC, 1  mol/L) significantly inhibited the relax-
ation elicited by the supernatant from insulin-stimulated
platelets (Fig. 3 a). Moreover, inclusion of adenosine deam-
inase in the supernatant to convert adenosine to inosine
significantly inhibited the relaxing effect of the supernatant
from insulin-stimulated platelets (Fig. 3 b). Neither the P2
purinoceptor antagonist, pyridoxal phosphate-6-azo(ben-
zene-2,4-disulfonic acid) tetrasodium salt (50  mol/L), nor
the P2Y receptor antagonist 3 -phosphoadenosine 5 -phos-
phosulfate (10  mol/L) affected the relaxation elicited by
insulin-stimulated platelets (not depicted).
Effect of Adenosine and Purine Receptor Antagonists on the
Adenosine- and ATP-induced Relaxation of the Porcine Coro-
nary Artery. Since ATP would be expected to be released
in larger amounts than adenosine from insulin-stimulated
platelets, concentration–relaxation curves to adenosine
(0.01–0.5  mol/L) and ATP (0.1–30  mol/L) were as-
sessed using endothelium-intact rings of porcine coronary
artery preconstricted with U46619.
The adenosine receptor antagonist CPT (10  mol/L)
significantly inhibited relaxations elicited by adenosine and
ATP (Fig. 3, c and e); Rmax values were 100   0.1 versus 44  
5.2% in solvent- and CPT-treated artery rings stimulated
with adenosine (P   0.01, n   5) and 85   7 versus 33  
6% in solvent- and CPT-treated artery rings stimulated with
ATP (P   0.01, n   5). A similar effect was observed in
adenosine- and ATP-stimulated coronary artery rings
treated with CSC (Fig. 3, d and f); Rmax values were 95   3
versus 12   6% in solvent- and CSC-treated artery rings
stimulated with adenosine (P   0.01, n   5) and 95   5
versus 32   8% in solvent- and CSC-treated artery rings
stimulated with ATP (P   0.01, n   6). Neither of the pu-
rinoceptor antagonists, pyridoxal phosphate-6-azo(benzene-
2,4-disulfonic acid) tetrasodium salt (50  mol/L) or 3 -
phosphoadenosine 5 -phosphosulfate (10  mol/L) affected
the relaxation elicited by adenosine or ATP (not depicted).
Similar results were obtained using endothelium-denuded
porcine coronary arteries (not depicted).
Insulin-stimulated and NO-dependent Release of ATP and
Adenosine from Washed Human Platelets. To determine
whether the release of ATP and/or adenosine in response
to insulin stimulation could account for the platelet-
derived relaxing factor, we assessed ATP and adenosine
levels in the supernatant of platelets incubated with either
solvent or insulin in the absence and presence of inhibitors
of the NO–cyclic GMP signaling pathway and compared
the results obtained with the ability of the same supernatant
to elicit the relaxation of precontracted rings of porcine
coronary artery.
In experiments in which insulin elicited the generation of
a platelet-derived relaxing factor, there was a significant, in-
sulin-induced release of ATP from platelets (Fig. 4 a). How-
ever, ATP levels were not increased by insulin in samples
(non responders) which failed to relax the arterial rings. The
insulin-induced release of ATP was attenuated by L-NA
and by NS2028 (10  mol/L) and the KT 5823 (1  mol/L).
On the other hand, both the NO donor DETA-NONOate
Figure 4. Insulin-stimulated and NO-dependent release of ATP and
adenosine from washed human and murine platelets. (a) Effect of L-NA
(300   mol/L, 30 min), the guanylyl cyclase inhibitor, NS 2028 (10
 mol/L, 30 min), and the G kinase inhibitor, KT 5823 (1  mol/L, 30 min),
on the insulin (1  mol/L, 10 min)-induced release of ATP from washed
human platelets. (b) Effect of L-NA (300  mol/L, 30 min) on the release
of adenosine from washed human platelets incubated with either solvent
(Sol) or insulin (1  mol/L, 10 min). In some experiments, adenosine
deaminase (50 U/ml) was added to the supernatant before stimulation. In
each case, the ability of the supernatant to relax precontracted rings of
porcine coronary artery was assessed, and the results were divided into
two categories, i.e., the relaxation induced by the supernatant of insulin-
stimulated platelets was  60% (responders) or relaxation was  20% (non
responders). (c) Effect of insulin (1  mol/L, 10 min) and NO (DETA
NONOate, 1  mol/L, 10 min) on the release of ATP from platelets de-
rived from either wild-type (eNOS / ) or eNOS /  mice. Experiments
were performed in the presence of solvent (Sol), L-NA, or Rp-8CPT-
cGMPs (10  mol/L). The results shown represent the mean   SEM of
data obtained in 6–10 independent experiments; *P   0.05, **P   0.01,
and ***P   0.001 versus the response obtained using the supernatant from
insulin-stimulated platelets.NO-dependent Release of ATP and Adenosine from Insulin-stimulated Platelets 352
(1  mol/L) and the cyclic GMP analogue–G kinase activa-
tor Sp-cGMPS (10  mol/L) stimulated the release of ATP
from platelets. ATP concentrations were 574.9   21.25
versus 2,006.3   540.7 and 1,394.0   207.7 nmol/L ATP
in the supernatant of solvent-stimulated platelets versus
DETA-NONOate– and Sp-cGMPS–stimulated platelets
(P   0.01, n   5–6). The levels of ATP released from these
platelets did not elicit aggregation and were markedly lower
than the levels detected in the supernatant from thrombin-
stimulated platelets. The ATP concentration was 574.0  
21.3 nmol/L ATP in the supernatant of solvent-stimulated
platelets versus 4,567.0   794.0 nmol/L ATP in the super-
natant from thrombin-stimulated platelets (P   0.01, n  
6). Similar results were obtained when adenosine levels in
the supernatant were assayed (Fig. 4 b). Moreover, adeno-
sine levels in the supernatant were attenuated in the pres-
ence of adenosine deaminase (Fig. 4 b).
To clarify the role of eNOS in the regulation of ATP re-
lease, experiments were performed using platelets from ei-
ther wild-type or eNOS /  mice. Insulin induced the
release of ATP from platelets from wild-type mice, a re-
sponse that was sensitive to L-NA and Rp-8CPT-cGMPs
and mimicked by DETA NONOate (Fig. 4 c). Insulin
failed to elicit the release of ATP from platelets from
eNOS /  mice, whereas ATP was secreted in response to
the NO donor (Fig. 4 c).
Insulin-stimulated Dense Granule Secretion. To deter-
mine whether or not the ATP/adenosine was derived from
dense granules, we determined whether serotonin, a classi-
cal marker of dense granules, was also released from insu-
lin-stimulated platelets. Again, insulin elicited the release of
serotonin from those platelets that also generated a relaxing
factor but not from platelets which failed to generate a re-
laxing factor (Fig. 5 a).
Effect of Insulin on the Association of Syntaxin 2 and VAMP-3.
Since dense granule release is inhibited by antibodies
against the target membrane soluble N-ethylmaleimide–
sensitive factor attachment protein receptor (t-SNARE)
protein syntaxin 2 (21) and by soluble recombinant
VAMP-3 (22), we determined whether or not insulin stim-
ulated the NO-dependent association of VAMP-3 with
syntaxin 2.
In unstimulated platelets, a small amount of VAMP-3
coprecipitated with syntaxin 2. Stimulation with either the
potent platelet activator thrombin (0.1 U/ml) or the NO
donor diethylamine nonoate (DETA-NO, 1  M, 10 min)
increased the association of VAMP-3 with syntaxin 2 (Fig.
5, b and d).
In platelets in which insulin elicited the L-NA–sensitive
and G kinase–dependent phosphorylation of VASP (an in-
dex of NO production), there was also an increased associ-
ation of VAMP-3 with syntaxin 2 (Fig. 5, c and d). The as-
sociation of these proteins was also sensitive to L-NA and
Rp-8CPT-cGMPs (10  mol/L). No change in the associ-
ation of VAMP-3 with syntaxin was observed in platelets
in which insulin did not elicit the phosphorylation of
VASP (not depicted).
Effect of Insulin on the Activation of  IIb 3 Integrin and the
Secretion of  -Granules. Neither insulin nor DETA
NONOate activated  IIb 3 integrin, as assessed using a
FITC-conjugated PAC1 antibody that recognizes only the
activated conformation of the  IIb 3 complex (Fig. 6).
Moreover, neither stimulus elicited the cell surface expres-
sion of P-selectin. These observations contrasted markedly
with the effects of thrombin, which both activated  IIb 3
integrin and elicited the cell surface expression of P-selectin
(Fig. 6). Insulin also failed to effect either the release of the
 -granule marker  -thromboglobulin or the generation of
thromboxane A2 (not depicted).
Discussion
The results of the present investigation demonstrate that
insulin-stimulated platelets release sufficient amounts of
ATP and/or adenosine to relax precontracted porcine cor-
onary arteries. The signaling pathway initiated by insulin
involves the activation of platelet eNOS, the soluble gua-
nylyl cyclase and G kinase, and the association of VAMP-3
Figure 5. Effect of insulin on serotonin release from  -granules, the
phosphorylation of VASP, and the association of VAMP-3 with syntaxin
2. (a) Effect of L-NA (300  mol/L) on the insulin-induced release of
serotonin from washed human platelets. Values are presented relative to
the serotonin levels detected in the supernatant from platelets treated with
solvent. The supernatant-induced relaxation of porcine coronary artery
rings was assessed, and the results were divided into two categories, i.e.,
responders and nonresponders. (b) Effect of solvent (CTL), thrombin
(Thr, 0.1 U/ml), and the NO donor DETA-NONOate (NO,1  mol/L)
on the association of VAMP-3 with syntaxin 2, immunoprecipitated from
washed human platelets. (c) Effect of solvent (CTL) and insulin (1  mol/L)
on the association of VAMP-3 with syntaxin 2, immunoprecipitated from
washed human platelets. Experiments were performed in the absence and
presence of L-NA and the G kinase inhibitor Rp-8CPT-cGMPs (Rp,
10  mol/L). The phosphorylation of VASP (Ser239 VASP), as a marker of
NOS activation, was also determined in the Triton X-100–soluble fraction
of the same platelets preparations. To demonstrate the equal loading of
each lane, the blots were reprobed with antibodies recognizing either
syntaxin 2 or total VASP protein. The bar graph (d) summarizes the results
of VAMP-3 association with syntaxin 2 obtained in seven independent
experiments. *P   0.05 and **P   0.01 versus unstimulated platelets
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with the t-SNARE protein, syntaxin 2, and the release of
adenine nucleotides and serotonin from dense granules.
Since insulin-induced vasodilatation in vivo is sensitive to
NOS inhibitors (8) but insulin does not acutely enhance
NO production by endothelial cells (20), the NO-depen-
dent release of platelet-derived vasodilator compounds may
well account for the phenomenon of insulin-induced va-
sodilatation in vivo.
The effects of insulin on platelets is controversial since
some studies have demonstrated that insulin attenuates
thrombin-induced platelet aggregation (23–25), whereas
others report that insulin may enhance platelet activation
and aggregation (26). The results of the present study sug-
gest that insulin activates platelets to a certain extent but
that the effects initiated stop short of the threshold for a
classical activation response. Indeed, although insulin elic-
ited the release of ATP and serotonin from platelets, the
amount of ATP and serotonin released was much smaller
than that released from thrombin-stimulated platelets.
Moreover, insulin and NO failed to either activate  IIb 3
integrin (the GPIIb–IIIa complex) or to induce  -granule
secretion, as determined by assaying the release of  -throm-
boglobulin and the surface expression of P-selectin.
The effect of insulin on the release of ATP, adenosine,
and serotonin from platelets was dependent on the genera-
tion of NO, since the responses were prevented by a NOS
inhibitor and by inhibitors of the guanylyl cyclase and G ki-
nase. Moreover, the NO donor, DETA-NO, mimicked the
effect of insulin and elicited the degranulation of human and
murine platelets, whereas insulin-induced ATP release was
not detectable in platelets from eNOS /  mice. The path-
way leading to the activation of eNOS in insulin-stimulated
platelets has not been completely elucidated but is thought
to involve the activation of the metabolic stress-sensing ki-
nase, AMPK (20). Given that changes in AMPK expression
and activity have been associated with insulin resistance and
diabetes (27, 28), alterations in AMPK activity may be
linked to aggregatory disturbances in diabetic patients. The
involvement of the AMPK in the insulin-induced release of
a platelet-derived relaxing factor was also indicated in the
present study, since relaxation was attenuated in samples
from platelets treated with the AMPK inhibitor iodotuber-
cidin. Although it has been reported that one of the inhibi-
tors used, KT 5823, does not inhibit G kinase in intact hu-
man platelets (29), we observed similar effects using KT
5823 and Rp-8CPT-cGMPs, and in our hands, KT 5823
attenuated the insulin-induced phosphorylation of VASP in
washed human platelets (unpublished data).
The existence of platelet-derived relaxing factors is
widely accepted (30), but the physiological relevance of the
release of these compounds is not generally appreciated.
The results of the present investigation indicate that the re-
lease of ATP/ADP and adenosine from insulin-stimulated
platelets can account for insulin-induced platelet-depen-
dent relaxation of porcine coronary arteries. Although
platelet-derived serotonin does elicit vasodilatation in some
vascular beds (16), serotonin failed to affect porcine coro-
nary artery tone (unpublished data). Although platelet-
derived adenine nucleotides and serotonin were proposed
to elicit vasodilatation by initiating the generation of an en-
dothelium-derived relaxing factor (15), the responses ob-
served to platelet-derived ATP/ADP and adenosine in the
present study were endothelium independent, and the re-
laxant response was mediated entirely via the activation of
Figure 6. Comparison of the effects of
insulin, NO, and thrombin on the activation
of   IIb 3 integrin and platelet  -granule
secretion.  Representative FACS® analysis
showing the effects of stimulation (10 min)
with either solvent (CTL), insulin (Ins, 1
 mol/L), DETA NONOate (NO, 1
 mol/L), or thrombin (Thr, 0.1 U/ml) on
the surface expression of activated  IIb 3
integrin (PAC1) or P-selectin. Identical
results were obtained in four additional
experiments. The dashed line represents the
population of unlabeled platelets.NO-dependent Release of ATP and Adenosine from Insulin-stimulated Platelets 354
adenosine receptors, especially the A2A-adenosine receptor.
The fact that the ATP-induced relaxation of coronary ar-
teries was insensitive to purinoceptor antagonists but was
markedly attenuated by adenosine receptor antagonists im-
plies that ATP is rapidly metabolized by the ecto-5 -nucle-
otidase within the vascular wall, as described previously
(31–33). The concept that adenosine mediates insulin-
induced vasodilatation is supported by forearm blood flow
data obtained in healthy subjects in response to a hyperin-
sulinemic euglycemic clamp, since both draflazine (an
adenosine uptake blocker) and theophylline (an adenosine
receptor antagonist) significantly prevented insulin-induced
changes in blood flow (5).
ATP, adenosine, and serotonin are stored within plate-
let-dense granules, and the molecular mechanisms of plate-
let exocytosis are thought to be homologous to those in
neurons and other cells in that SNARE complexes are
formed between VAMPs and proteins in the target mem-
branes (t-SNAREs) (34). Platelet membranes contain the
t-SNARE proteins syntaxins 2 and 4, which play distinc-
tive roles in granule exocytosis, with syntaxin 2 being in-
volved in dense granule release (35). Platelets also contain
abundant amounts of SNAP-23 (36) and VAMP-3 and -8
(22;37), which interact and form SNARE complexes (for
review see reference 34). Since dense granule release is re-
ported to be inhibited by antibodies against the syntaxin 2
(21) and by soluble recombinant VAMP-3 (22), we deter-
mined the effects of insulin on the association of syntaxin 2
and VAMP-3. We observed that insulin initiated the asso-
ciation of the two proteins and that this effect is also depen-
dent on the activation of eNOS and the G kinase. More-
over, a NO donor also stimulated the association of the
two proteins and the association of syntaxin 2 with VAMP-3
was only detected in samples in which insulin induced the
L-NA–sensitive phosphorylation of VASP as a marker for
eNOS activation.
Although all of the platelets derived from wild-type mice
responded to insulin with an increase in ATP release,
 35% of the human platelet preparations used did not re-
spond to insulin. This phenomenon was not donor specific
since a responder could be nonresponder at a different
bleeding time and vice versa. Heterogeneity in responsive-
ness to insulin is well documented (38) and can be related
to numerous factors including physical condition (39). Al-
though it was outside the scope of the present study to de-
termine the mechanisms affecting insulin sensitivity, we
found an excellent correlation between the insulin-induced
activation of platelet eNOS (assayed via cyclic GMP), the
release of a platelet-derived relaxing factor, the association
of VAMP-3 with syntaxin 2 and dense granule secretion.
In all cases in which insulin activated platelet eNOS, the
entire signaling cascade leading to dense granule secretion
was also activated. This implies that the phenomenon de-
termining insulin resistance is located upstream of the acti-
vation of eNOS.
There appear to be at least two actions of NO in plate-
lets. The first is to limit platelet activation, adhesion, and
aggregation by activating the soluble guanylyl cyclase, in-
itiating the G kinase–mediated phosphorylation of the
thromboxane receptor (40), inhibiting kinase activity (41,
42) and decreasing capacitative Ca2  entry (43, 44). A sec-
ond effect of NO in platelets appears to be to facilitate the
release of ATP/ADP and serotonin from dense granules via
a G kinase–dependent pathway involving the association of
VAMP-3 with syntaxin 2. This implies that low concentra-
tions of NO actually promote platelet activation. However,
rather than being a proaggregatory signal, the limited de-
granulation that occurs in response to insulin-induced NO
production results in the release of potent vasodilator com-
pounds. These data are consistent with a recent report
demonstrating that cyclic GMP enhances thrombin-induced
platelet activation, whereas G kinase inhibitors attenuate
the response (45). The role of the G kinase in mediating
platelet responses is reported to be biphasic, consisting of an
initial transient stimulatory response that promotes platelet
aggregation and a subsequent inhibitory response that lim-
ited thrombus size (45).
How can the apparently contradictory effects of the
NO–cyclic GMP–G kinase pathway on platelet activation
be reconciled? Although it is impossible to answer this
question at this stage, the key is probably related to further
factors, i.e., the platelet microenvironment and the concom-
itant activation of additional signaling pathways. Indeed, al-
though the von Willebrand factor- and thrombin-induced
activation of platelets is impaired in G kinase–deficient
mice (45), the response to collagen is normal (46).
Together, the results of the present investigation, some-
what heretically, suggest that the acute vasodilator action of
insulin, which has until now been attributed to the genera-
tion of endothelium-derived NO, can actually be attrib-
uted to the effect of the hormone on platelet eNOS and
the subsequent release of adenine nucleotides, which are
rapidly metabolized by the ectonucleotidase present on the
endothelial cell surface to the potent vasodilator adenosine.
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